Cargando…

Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent

INTRODUCTION: Pharmacologic therapy options for COVID-19 should include antiviral, anti-inflammatory, and anticoagulant agents. With the limited effectiveness, currently available virus-directed therapies may have a substantial impact on global health due to continued reports of mutant variants affe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tantry, Udaya S, Schror, Karsten, Navarese, Eliano Pio, Jeong, Young-Hoon, Kubica, Jacek, Bliden, Kevin P, Gurbel, Paul A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665864/ https://www.ncbi.nlm.nih.gov/pubmed/34908882 http://dx.doi.org/10.2147/JEP.S330776

Ejemplares similares

IS LOW DOSE ASPIRIN EFFECTIVE IN REDUCING IN-HOSPITAL CLINICAL OUTCOMES IN PATIENTS WITH COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

Further evidence for the use of aspirin in COVID-19
por: Tantry, Udaya S., et al.
Publicado: (2022)

High-Dose, but Not Low-Dose, Aspirin Impairs Anticontractile Effect of Ticagrelor following ADP Stimulation in Rat Tail Artery Smooth Muscle Cells
por: Grześk, Grzegorz, et al.
Publicado: (2013)

Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials
por: Navarese, Eliano Pio, et al.
Publicado: (2012)

State of the art: Oral antiplatelet therapy
por: Gurbel, Paul A, et al.
Publicado: (2016)

Can an Old Ally Defeat a New Enemy?
por: Gurbel, Paul A., et al.
Publicado: (2020)

IS THERE A ROLE FOR α1-ANTITRYPSIN IN COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

AGE-BASED RISK FACTORS FOR SYMPTOMATIC COVID-19 IN THE MINORITY POPULATION
por: Gurbel, Paul A., et al.
Publicado: (2021)

Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population
por: Gurbel, Paul A., et al.
Publicado: (2021)

Statins and Risk of New-Onset Diabetes Mellitus: is there a Rationale for Individualized Statin Therapy?
por: Navarese, Eliano Pio, et al.
Publicado: (2013)

PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection
por: Navarese, Eliano P., et al.
Publicado: (2023)

In Vitro Evidence for the Role of Cytokine Storm in the Generation of Stent Thrombosis in COVID-19 Patients
por: Gurbel, Paul A., et al.
Publicado: (2022)

Risk of Statin-Induced Hypertransaminasemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Villani, Rosanna, et al.
Publicado: (2019)

Genetic determinants of platelet response to clopidogrel
por: Kubica, Aldona, et al.
Publicado: (2011)

Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations
por: Chaudhary, Rahul, et al.
Publicado: (2020)

Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction
por: Swiatkiewicz, Iwona, et al.
Publicado: (2012)

ACS network-based implementation of therapeutic hypothermia for the treatment of comatose out-of-hospital cardiac arrest survivors improves clinical outcomes: the first European experience
por: Kozinski, Marek, et al.
Publicado: (2013)

Value of C-Reactive Protein in Predicting Left Ventricular Remodelling in Patients with a First ST-Segment Elevation Myocardial Infarction
por: Swiatkiewicz, Iwona, et al.
Publicado: (2012)

Influence of Race and Sex on Thrombogenicity in a Large Cohort of Coronary Artery Disease Patients
por: Lev, Eli I., et al.
Publicado: (2014)

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
por: Gurbel, Paul A., et al.
Publicado: (2018)

Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes
por: Usman, Abira, et al.
Publicado: (2022)

IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study
por: Kubica, Jacek, et al.
Publicado: (2022)

Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
por: Gurbel, Paul A, et al.
Publicado: (2010)

Personalized antiplatelet therapy: state of the art
por: Gurbel, Paul A, et al.
Publicado: (2012)

Temporal Variability of Platelet Reactivity Phenotype: Another Barrier to Personalized Antiplatelet Strategy Guided by Platelet Function Testing
por: Jeong, Young-Hoon, et al.
Publicado: (2019)

International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests
por: Gurbel, Paul A., et al.
Publicado: (2021)

First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19
por: Tantry, Udaya S, et al.
Publicado: (2021)

Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial
por: Park, Hyun-Woong, et al.
Publicado: (2021)

The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?
por: Altman, Raul, et al.
Publicado: (2004)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2019)

Pharmacological adjuncts to stop bleeding: options and effectiveness
por: Panteli, M., et al.
Publicado: (2015)

Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study
por: Niezgoda, Piotr, et al.
Publicado: (2022)

Long-term outcome of rotational atherectomy according to burr-to-artery ratio and changes in coronary artery blood flow: Observational analysis
por: Nowak, Aleksander, et al.
Publicado: (2022)

Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients
por: Kubica, Jacek, et al.
Publicado: (2023)

Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus
por: Jung, Jung Hwa, et al.
Publicado: (2015)

Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can “Thrombin Pathway” Be a New Target for Therapy?
por: Kim, Hyun Kuk, et al.
Publicado: (2020)

Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial
por: Kubica, Jacek, et al.
Publicado: (2016)

Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint
por: Kubica, Jacek, et al.
Publicado: (2023)

ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial
por: Kubica, Aldona, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0erse0rjn3ipnmoqv62cvenv2f